X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
female (45) 45
male (44) 44
aged (43) 43
middle aged (42) 42
lung neoplasms - drug therapy (37) 37
carcinoma, non-small-cell lung - drug therapy (35) 35
adult (33) 33
oncology (33) 33
index medicus (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
lung neoplasms - mortality (21) 21
lung neoplasms - pathology (20) 20
gefitinib (19) 19
treatment outcome (19) 19
carcinoma, non-small-cell lung - mortality (18) 18
carcinoma, non-small-cell lung - pathology (18) 18
chemotherapy (17) 17
aged, 80 and over (15) 15
neoplasm staging (15) 15
disease-free survival (13) 13
lung cancer, non-small cell (13) 13
cancer (12) 12
respiratory system (12) 12
survival analysis (12) 12
survival rate (12) 12
antineoplastic agents - therapeutic use (11) 11
cisplatin - administration & dosage (11) 11
non-small cell lung cancer (11) 11
survival (11) 11
therapy (11) 11
cisplatin (10) 10
docetaxel (10) 10
lung neoplasms - genetics (10) 10
carboplatin - administration & dosage (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
care and treatment (9) 9
deoxycytidine - analogs & derivatives (9) 9
lung cancer (9) 9
paclitaxel - administration & dosage (9) 9
protein kinase inhibitors - therapeutic use (9) 9
quinazolines - therapeutic use (9) 9
analysis (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
asia (8) 8
deoxycytidine - administration & dosage (8) 8
erlotinib (8) 8
nsclc (8) 8
open-label (8) 8
receptor, epidermal growth factor - genetics (8) 8
thailand (8) 8
trial (8) 8
adenocarcinoma (7) 7
double-blind method (7) 7
quality of life (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
antineoplastic agents - adverse effects (6) 6
cell lung-cancer (6) 6
erlotinib hydrochloride (6) 6
gemcitabine (6) 6
hematology, oncology and palliative medicine (6) 6
kaplan-meier estimate (6) 6
mutation (6) 6
proportional hazards models (6) 6
prospective studies (6) 6
drug administration schedule (5) 5
egfr (5) 5
follow-up studies (5) 5
medicine, general & internal (5) 5
multicenter (5) 5
non-small-cell lung cancer (5) 5
phase-iii trial (5) 5
prognosis (5) 5
quinazolines - administration & dosage (5) 5
quinazolines - adverse effects (5) 5
1st-line treatment (4) 4
adenocarcinoma - drug therapy (4) 4
adenocarcinoma - genetics (4) 4
adenocarcinoma - pathology (4) 4
adolescent (4) 4
asian continental ancestry group (4) 4
carboplatin (4) 4
clinical trials (4) 4
disease progression (4) 4
dose-response relationship, drug (4) 4
egfr mutations (4) 4
medical colleges (4) 4
pemetrexed (4) 4
pulmonary and respiratory medicine (4) 4
pulmonary/respiratory (4) 4
randomized controlled trials as topic (4) 4
risk assessment (4) 4
risk factors (4) 4
tumors (4) 4
adenocarcinoma - mortality (3) 3
afatinib (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S143 - S144
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | FACTOR-RECEPTOR GENE | MULTICENTER | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2005, Volume 353, Issue 2, pp. 123 - 132
Journal Article
Journal Article
Journal Article
Value in Health Regional Issues, ISSN 2212-1099, 05/2020, Volume 21, pp. 9 - 16
To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. A Markov model comprising 3 health... 
non-small cell lung cancer | pemetrexed | cost-effectiveness analysis | Thailand
Journal Article
Hepatology, ISSN 0270-9139, 09/2016, Volume 64, Issue 3, pp. 774 - 784
Journal Article